Clementine Cherry Hill Now Open to Treat Adolescents of All Genders with Eating Disorders
12 Oct 2022
Cherry Hill location is Monte Nido & Affiliates' first program in the state of New Jersey
CHERRY HILL, N.J., Oct. 12, 2022 /PRNewswire/ -- Monte Nido & Affiliates, one of the largest and leading eating disorder treatment providers in the country, today announces the opening of Clementine Cherry Hill located in Cherry Hill, N.J. The company's newest residential eating disorder center will provide care for adolescents of all genders with anorexia nervosa, bulimia nervosa, binge eating disorder and/or exercise addiction. Expanding to its 15th state, Clementine Cherry Hill is the provider's first program in the state of New Jersey.
Continue Reading
The new Cherry Hill facility will allow more teens in New Jersey to get the help they need and become fully recovered.
Tweet this
Preview
Source: PRNewswire
Clementine Cherry Hill, a new residential eating disorder treatment program for adolescents in Cherry Hill, New Jersey.
"At Clementine, our goal is to help make treatment accessible and we are committed to expanding care for even more people in pursuit of recovery," said Candy Henderson, MS, Chief Executive Officer of Monte Nido & Affiliates. "With eating disorders on the rise among adolescents, the new Cherry Hill facility will allow more teens in New Jersey to get the help they need and become fully recovered."
In the comfort of a home-like setting, Clementine Cherry Hill provides the highest level of medical and psychiatric care outside of a hospital, incorporating family and academic support, 24-hour nursing and mindful eating practices. The residential program offers individualized, evidence-based treatment that focuses on restoring physiological and nutritional balance.
"We are always sensitive to the developmental needs of this younger population, so the Clementine model of care was created using evidence-based modalities backed by research outcomes that demonstrate the efficacy of our care," said Melissa Spann, PhD, LMHC, CEDS-S, Chief Clinical Officer of Monte Nido & Affiliates. "Adolescents are particularly susceptible to eating disorders due to the developmental stages they are at in their lives, so early intervention is essential – and recovery is possible with the right tools and support."
Eating disorders have the second highest mortality rate of any mental health illness and can affect adolescents of all ages, genders and body types. Expanding access to care is an important part of early intervention and treatment, which offers adolescents with an eating disorder a greater chance of recovery.
For more information, or to inquire about treatment at Clementine Cherry Hill, please go to www.clementineprograms.com or call 855-900-2221.
About Monte Nido & Affiliates
Monte Nido & Affiliates is one of the country's largest and leading eating disorder platforms, offering inpatient, residential, and day treatment programs for eating disorders. Founded in 1996, Monte Nido & Affiliates currently operates forty-nine programs in fifteen states, with residential programs being Joint Commission accredited. Monte Nido & Affiliates includes five distinct eating disorder program brands: Monte Nido, Walden Behavioral Care, Rosewood Centers, Oliver-Pyatt Centers, and Clementine.
Contact: Claire Vartabedian or Abigail Cox
L.C. Williams & Associates
312-565-3900
[email protected]
SOURCE Monte Nido & Affiliates
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.